AU4556499A

AU4556499A – Temperature-sensitive liposomal formulation
– Google Patents

AU4556499A – Temperature-sensitive liposomal formulation
– Google Patents
Temperature-sensitive liposomal formulation

Download PDF
Info

Publication number
AU4556499A

AU4556499A
AU45564/99A
AU4556499A
AU4556499A
AU 4556499 A
AU4556499 A
AU 4556499A
AU 45564/99 A
AU45564/99 A
AU 45564/99A
AU 4556499 A
AU4556499 A
AU 4556499A
AU 4556499 A
AU4556499 A
AU 4556499A
Authority
AU
Australia
Prior art keywords
liposome
active agent
liposomes
lysolipid
agents
Prior art date
1998-06-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Application number
AU45564/99A
Other versions

AU749806B2
(en

Inventor
David Needham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Duke University

Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1998-06-18
Filing date
1999-06-09
Publication date
2000-01-05

1999-06-09
Application filed by Duke University
filed
Critical
Duke University

2000-01-05
Publication of AU4556499A
publication
Critical
patent/AU4556499A/en

2002-07-04
Application granted
granted
Critical

2002-07-04
Publication of AU749806B2
publication
Critical
patent/AU749806B2/en

2019-06-09
Anticipated expiration
legal-status
Critical

Status
Expired
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K9/00—Medicinal preparations characterised by special physical form

A61K9/10—Dispersions; Emulsions

A61K9/127—Liposomes

A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K9/00—Medicinal preparations characterised by special physical form

A61K9/10—Dispersions; Emulsions

A61K9/127—Liposomes

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P31/04—Antibacterial agents

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P35/00—Antineoplastic agents

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P37/00—Drugs for immunological or allergic disorders

A61P37/02—Immunomodulators

A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

Temperature sensitive liposomes containing active agents are described. The liposomes comprise phospholipids and a surface active agent, such as a lysolipid, that increases the amount of active agent released by the liposome at the phase transition temperature of the liposome. Such liposomes are useful in methods of administering active agents using mild hyperthermic conditions.

Description

WO 99/65466 PCT/US99/12964 TEMPERATURE-SENSITIVE LIPOSOMAL FORMULATION This invention was made with Government support under National Institutes of Health grant NIH GM40162 and National Cancer Institute SPORE grant P50-CA68438. The Government may have certain rights to this invention. 5 Field of the Invention The present invention relates to thermosensitive liposomes, and more specifically to liposomes comprising phospholipids and a surface active agent, wherein the liposomes release their contents at mild hyperthermic temperatures. 10 Background of the Invention Liposomes consist of at least one lipid bilayer membrane enclosing an aqueous internal compartment. Liposomes may be characterized by membrane type and by size. Small unilamellar vesicles (SUVs) have a single membrane and typically range between 0.02 and 0.05 tm in diameter; large unilamellar vesicles 15 (LUVs) are typically larger than 0.05pm. 01iglamellar large vesicles and multilamellar large vesicles have multiple, usually concentric, membrane layers and are typically larger than 0.1 m. Liposomes with several nonconcentric membranes, i.e., several small vesicles contained within a larger vesicle, are termed multivesicular vesicles.
WO 99/65466 PCT/US99/12964 Conventional liposomes are formulated to carry therapeutic agents, drugs or other active agents either contained within the aqueous interior space (water soluble active agents) or partitioned into the lipid bilayer (water-insoluble active agents). Copending US patent application SN 08/795,100 discloses liposomes 5 containing cholesterol in the lipid bilayer membrane, where an active agent is aggregated with a lipid surfactant to form micelles and the micelles are entrapped in the interior space of the liposome. Active agents that have short half-lives in the bloodstream are particularly suited to delivery via liposomes. Many anti-neoplastic agents, for example, are 10 known to have a short half-life in the bloodstream such that their parenteral use is not feasible. However, the use of liposomes for site-specific delivery of active agents via the bloodstream is limited by the rapid clearance of liposomes from the blood by cells of the reticuloendothelial system (RES). Liposomes are normally not leaky but will become so if a hole occurs in the 15 liposome membrane, if the membrane degrades or dissolves, or if the membrane temperature is increased to the phase transition temperature. The elevation of temperature (hyperthermia) at a target site in a subject to raise liposome temperature above the phase transition temperature, and thereby cause the release of the liposome contents, has been used for the selective delivery of therapeutic 20 agents. Yatvin et al., Science 204:188 (1979). This technique is limited, however, where the phase transition temperature of the liposome is significantly higher than the normal tissue temperature. It is accordingly desirable to devise liposome formulations capable of delivering therapeutic amounts of active agents in response to mild hyperthermic 25 conditions. Summary of the Invention In view of the foregoing, a first aspect of the present invention is a liposome containing an active agent. The liposome’s lipid bilayer membrane 30 contains phospholipids as the primary lipid source; lysolipids are contained in the bilayer membrane in an amount that increases the percentage of active agent 2 WO 99/65466 PCT/US99/12964 released at the phase transition temperature, compared to that which would occur in the absence of lysolipid. A further aspect of the present invention is a liposome having a lipid bilayer membrane comprising phospholipids as the primary lipid source, and 5 from 2 mole percent to 30 mole percent lysolipid. A further aspect of the present invention is a method for preparing an active agent for hyperthermic administration. The active agent is entrapped in a liposome having a lipid bilayer membrane comprising phospholipids as the primary lipid source, and from 1 to 30% lysolipid. 10 A further aspect of the present invention is a liposomal preparation comprising a plurality of liposomes as described above. A further aspect of the present invention is a method of making liposomes containing an active agent in the liposome interior space. A phospholipid film containing lysolipid is first prepared, and then hydrated with an aqueous 15 preparation containing the active agent and an equilibrating amount of lysolipid monomer. Lysolipid is contained in the liposome membrane in an amount sufficient to increase the percentage of active agent released at the phase transition temperature of the liposome membrane, compared to that which would occur in the absence of the lysolipid. 20 Brief Description of the Drawings Figure 1 schematically represents a liposome having a bilayer membrane containing dipalmitoylphosphatidylcholine (DPPC) as a phospholipid and monopalmitoylphosphatidylcholine (MPPC) as a lysolipid. The orientation of the 25 lysolipid monomers and their presence in both the inner and outer layers of the lipid bilayer is indicated. Figure 2 graphs the effect of extrusion pass on the mean diameter of DPPC liposomes containing DPPC:MPPC (90:10). Multilamellar vesicles with an average size of 700 nm were extruded through a stack of two polycarbonate 30 membranes of pore size 0.1 mM under a pressure of 300-400 psi at 45 0 C. 3 WO 99/65466 PCT/US99/12964 Figure 3 graphs the release of 6-Carboxyfluorescein (CF) entrapped in liposomes composed of DPPC:MPPC (90:10), as a function of time in the presence of PBS at 370 (open circles) and 400 C (closed squares). Figure 4 graphs the release of CF from DPPC:MPPC liposomes of 5 varied concentrations, at temperatures between 20 0 C and 45 0 C in the presence of 10 mM PBS (pH= 7.4). Liposomes contained DPPC alone (open circles); DPPC:MPPC 98:2 (closed squares); DPPC:MPPC 96:4 (closed triangles A); DPPC:MPPC 94:6 (open triangles V); DPPC:MPPC 93:7 (closed diamonds); DPPC:MPPC 92:8 (open squares); DPPC:MPPC 90:10 (closed circles); 10 DPPC:MPPC 80:20 (closed triangles V). Figure 5A provides heat flow thermograms showing the effect of varied MPPC concentration on the -phase transition temperature (Tc) of DPPC liposomes. The Tc of lyophilized liposomal samples of DPPC containing MPPC (1-10 mol%) was measured by Differential Scanning Calorimetry (DSC) between 15 30 0 C-45 0 C with 2 Co/minute heating rate. Figure 5B graphs the effect of MPPC concentration on the phase transition temperature (Tc) of DPPC liposomes, as described above for Figure 5A. The graph shows the start point of the transition (open circle); the peak in enthalpy (closed circle); and the end point of the transition (open triangle). 20 Figure 6A compares the differential scanning calorimetric profile (excess heat flow; open squares) of liposomes (90:10 DPPC:MPPC) with the differential release profile (solid circles) for 6-Carboxyfluorescein (CF) release, as obtained from the cumulative release experiment described in Figure 4. Figure 6B graphs the differential release profile from 90:10 25 DPPC:MPPC liposomes, where open circles represent heat flow and solid circles represent differential release of CF over temperatures of from 25 0 C to 45 0 C. Figure 7 graphs the release of entrapped Doxorubicin (DX) from liposomes (90:10 DPPC:MPPC) as a function of time at 37 0 C (solid circles) and 40 0 C (open circles) in the presence of PBS. 30 Figure 8 graphs the cumulative release profiles of entrapped DX from liposomes composed of 90:10 DPPC:MPPC, incubated at temperatures of between 25’C and 45 0 C for five minutes in the presence of PBS. Figure 9A graphs the release of entrapped 6-Carboxyfluorescein (CF) from liposomes (90:10 DPPC:MPPC incorporated with 5 mol% of DSPE 35 PEG2000) in the presence of PBS and as a function of temperature (37 0 C – open circle; 38 0 C – closed square; 39 0 C – closed triangle; 39.5 0 C – open triangle; and 40 0 C – closed circle). 4 WO 99/65466 PCT/US99/12964 Figure 9B graphs the release of entrapped 6-Carboxyfluorescein (CF) from liposomes (composed of 90:10 DPPC:MPPC and incorporated with 5 mol% of DSPE-PEG2000) in the presence of 50% bovine serum and as a function of temperature (37 0 C – open circle; 38 0 C – closed square; 39 0 C – closed 5 triangle; 39.5 0 C – open triangle; and 40 0 C – closed circle). Figure 10 graphs the cumulative release of entrapped 6 Carboxyfluorescein (CF) from liposomes composed of 90:10 DPPC:MPPC, at various temperatures from 250 to 45 0 C in the presence of PBS (closed circles) or 50% bovine serum (open circles). 10 Figure 11A shows the chemical structure of 1, 2-Dipalmitoyl-sn-Glycero 3-Phosphocholine (DPPC). Figure 11B shows the chemical structure of 1-Palmitoyl-2-Hydoxy-sn Glycero-3-Phosphocholine (MPPC). Figure 11C shows the chemical structure of 1, 2-Distearoyl-sn-Glycero 15 3-Phosphoethanolamine-N-[Poly(ethyleneglycol) 2000] (DSPE-PEG2000). Detailed Description of the Invention The present invention provides liposomes that are sensitive to alterations in the temperature of the surrounding environment. The temperature-sensitivity 20 of such liposomes allows the release of compounds entrapped within the interior aqueous space of the liposome, and/or the release of compounds associated with the lipid bilayer, at a target site that is either heated (as in the clinical procedure of hyperthermia) or that is at an intrinsically higher temperature than the rest of the body (as in inflammation). Liposome bilayers of the present invention 25 include (in addition to a primary or main lipid component) lysolipid, or another surface active agent(s). The inclusion of lysolipid or another surface active agent in the liposome bilayer enhances the release of compounds when the liposome temperature reaches the gel-to-liquid crystalline phase transition temperature of the primary lipid component. The presence of the lysolipid (or other surface 30 active agent) also causes the liposome to release the drug at a slightly lower temperature than that achieved with liposomes composed solely of phospholipids. Liposomes of the present invention are particularly useful in drug delivery, where the liposome contains a compound to be delivered to a preselected target site in a subject’s body. The target site is either artificially heated 35 (hyperthermia) so that it is at or above the gel-to-liquid crystalline phase transition temperature, or the target site may be at a higher temperature than non-targeted sites in the body due to natural causes (e.g., inflammation), where 5 WO 99/65466 PCT/US99/12964 that temperature is at or above the gel-to-liquid crystalline phase transition temperature of the liposome utilized. When liposomes are incubated for several minutes at temperatures in the region of the gel-to-liquid crystalline phase transition temperature (Tc) of the 5 primary lipid composing the liposome, the liposome bilayer becomes permeable and releases solutes entrapped within the liposome into the surrounding solution. The clinical use of hyperthermia with such thermally-sensitive liposomes has been proposed. See, e.g., Yatvin et al., Science 202:1290 (1978). US Patent No. 5,094,854 (Ogawa et al.) discloses liposomes in which the 10 osmotic pressure of the drug-containing solution entrapped in liposomes is 1.2 2.5 times higher than that of the body fluid of warm-blooded animals. The temperature range in which the liposome membrane becomes permeable to material release is stated to be in the range of 40’C to 450 C. US Patent No. 5,720,976 (Kim et al.) discloses the use of a copolymer of 15 N-isopropylacrylamide/octadecylacrylate/acrylic acid to coat the liposomal surface to effect the release of agents contained within the liposome. Release of the entrapped agent occurs at temperatures above 28 0 C (well below average human temperature). Methods of heating a subject’s body for therapeutic purposes or to assist 20 in the delivery of therapeutic or diagnostic agents are known in the art. Hyperthermia consists of heating diseased sites, such as solid tumors, to temperatures higher than the physiological temperature (e.g., from about 38 0 C to about 45’C), and is currently used mainly as an adjunct to radiation therapy (Bates and Mc Killop Cancer Res. 46:5477 (1986); Herman, Cancer Res. 43, 25 511 (1983)). As used herein, the term «hyperthermia» refers to the elevation of the temperature of a subject’s body, or a part of a subject’s body, compared to the normal temperature of the subject. Such elevation may be the result of a natural process (such as inflammation) or artificially induced for therapeutic or 30 diagnostic purposes. In mammals, a normal body temperature is ordinarily maintained due to the thermoregulatory center in the anterior hypothalamus, which acts to balance heat production by body tissues with heat loss. «Hyperthermia» refers to the elevation of body temperature above the hypothalamic set point due to insufficient heat dissipation. In contrast to 35 hyperthermia, «fever» refers to an elevation of body temperature due to a change in the thermoregulatory center. The overall mean oral temperature for a healthy human aged 18-40 years is 36.8 + 0.41C (98.2 + 0.7 0 F). See, e.g., Harrison’s 6 WO 99/65466 PCT/US99/12964 Principles of Internal Medicine (Fauci et al., Eds.) 14 ‘ Edition, McGraw-Hill, New York, p. 84 (1998). The use of hyperthermia with thermally-sensitive liposomes has been proposed, for example, for the treatment of tumors (Yatvin et al., Science 5 202:1290 (1978)). Using localized hyperthermia and thermally-sensitive liposomes to target anti-neoplastic agents to tumor sites in a subject acts to decrease undesirable side effects of the agent, and to enhance therapeutic results. However, the efficacy of liposomes targeted to diseased sites by hyperthermia depends on the stability of the liposome in the blood stream (when liposomes are 10 administered to the circulatory system), and on the amount of active agent released by the liposome at the target site. For example, liposomes described by Yatvin et al, Science 202:1290 (1978) released only a portion of the drug carried by the liposome at hyperthermic temperatures. As used herein, «hyperthermic administration» of an active agent refers to 15 its administration in conjunction with the use of clinical hyperthermia in the subject at a preselected target site, to deliver a larger amount of active agent to the target site compared to that which would result from the administration of the active agent in the absence of hyperthermia. Liposomes of the present invention comprise a lipid possessing a gel-to 20 liquid crystalline transition temperature in the hyperthermic range (e.g., the range of from approximately 380 C to approximately 450C). Preferred are phospholipids with a phase-transition temperature of from about 38 0 C to about 45 0 C, and more preferred are phospholipids whose acyl groups are saturated. A particularly preferred phospholipid is dipalmitoylphosphatidylcholine (DPPC). 25 DPPC is a common saturated chain (C16) phospholipid with a bilayer transition of 41.5 0 C (Blume, Biochemistry 22:5436 (1983); Albon and Sturtevant, Proc. Natl. Acad. Sci. USA 75:2258 (1978)). Thermosensitive liposomes containing DPPC and other lipids that have a similar or higher transition temperature, and that mix ideally with DPPC (such 1, 2-Dipalmitoyl-sn-Glycero-3-[Phospho-rac 30 (1-glycerol)] (DPPG) (Tc – 41.50 C) and 1, 2-Distearoyl-sn-Glycero-3 Phosphocholine (DSPC) (Tc 55.10 C)) have been studied. Kastumi Iga et al, Intl. J. Pharmaceutics, 57:241 (1989); Bassett et al, J. Urology, 135:612 (1985); Gaber et al, Pharmacol. Res. 12:1407 (1995). Thermosensitive liposomes containing DPPC and cholesterol have also been described. Demel and De 35 Kruyff, Biochim. Biophys. Acta. 457:109 (1976). As used herein, the «primary lipid» in a liposome bilayer is that which is the main lipid component of liposome bilayer material. Thus, in a liposome 7 WO 99/65466 PCT/US99/12964 bilayer composed of 70 mole% phospholipid and 30 mole% lysolipid, the phospholipid is the primary lipid. Liposomes of the present invention incorporate a relatively-water soluble surface active agent, such as a lysolipid, into a bilayer composed primarily of a 5 relatively water-insoluble molecule, such as a di-chain phospholipid (e.g., DPPC). Incorporation of the surface active agent in the gel phase of the primary lipid component enhances the release of contents from the resulting liposome when heated to the gel-liquid crystalline phase transition temperature of the primary lipid. Preferred surface active agents are lysolipids, and a particularly 10 preferred surface active agent is monopalmitoylphosphatidylcholine (MPPC). Suitable surface-active agents are those that are compatible with the primary lipid of the bilayer, and that desorb when the lipid melts to the liquid phase. Additional suitable surface-active agents for use in phospholipid bilayers include palmitoyl alcohols, stearoyl alcohols, palmitoyl, stearoyl, polyethylene glycol, 15 glyceryl monopaimitate, glyceryl monooleate, ceramides, PEG-ceramides, and therapeutic lipids. Therapeutic lipids include, for example, C-18 ether linked lysophoshpatidylchohline. A preferred liposome of the present invention incorporates a bilayer compatible lysolipid in a phospholipid bilayer, the lysolipid present in the bilayer 20 at a concentration sufficient to enhance the release of contents (e.g., active agent or therapeutic agent) from the liposome, compared to the release of contents that would be achieved using a liposome composed of only lipid alone (i.e., without lysolipid). The contents may be contained within the interior of the liposome or in the liposome membrane. By «enhanced release», it is meant that either (a) 25 that a greater percentage of contents is released at a given temperature, compared to the amount of contents released at that temperature by a lipsome with a bilayer composed of phospholipid only; or (b) the contents entrapped in the interior of the liposome are released at a lower temperature than the temperature at which release of contents would occur using a lipsome with a bilayer composed of 30 phospholipid only. The present invention provides liposomes that release entrapped contents at temperatures that can be achieved in clinical settings using mild hyperthermia. The present invention provides liposomes (THERMOSOMES T M ) that are highly stable at body temperature (37 0 C) but that become unstable and show enhanced 35 release of entrapped compounds at temperatures beyond about 39 0 C. This temperature range is a few degrees below that of many previous liposomal formulations that only showed significant release at temperatures greater than 8 WO 99/65466 PCT/US99/12964 42 0 C. Additionally, the present liposomal formulation’s combination of lipid and compatible lysolipid provides a lipid/lysolipid mixture with a slightly lower gel to-liquid crystalline transition temperature compared to that of pure lipid alone, yet the gel-to-liquid crystalline transition temperature is not broadened by the 5 inclusion of a lysolipid. A preferred liposome of the present invention has a bilayer composed primarily of phospholipid, and containing lysolipid in an amount that decreases the gel-to-liquid crystalline phase transition temperature of the bilayer, compared to a bilayer composed of phospholipid alone. A particularly preferred liposome 10 of the present invention comprises a DPPC as the primary phospholipid and MPPC as the lysolipid, where the ratio of DPPC:MPPC is from about 99:1, 98:2, 97:3, 96:4, 95:5, 90:10, to about 80:20, 75:25, 70:30, 65:35, 60:40, or even 51:49 (by molar ratio). The present invention provides a new system for delivering active agents 15 in a lipid carrier, wherein active agents are released from the carrier over a narrow temperature range. Local heating of target sites to mildly hyperthermic temperatures (i.e., 39 0 C to 41 0 C) allows preferential delivery of the active agent to a diseased site. The present liposomes are suited for use in combination with hyperthermia to target active agents to disease sites, compared to conventional 2 0 liposomes that only release active agents slowly and that are not thermosensitive, or compared to thermosensitive liposomes that do not release active agents unit reaching temperatures of 42 0 C or above. While not wishing to be held to any single theory of action, the present 25 inventors believe that the mechanism whereby lysolipids (or other surface active agents) enhance the release of contents from liposomes composed primarily of phospholipid is related to the way in which the lysolipid is mostly ideally mixed in the mixed gel phase bilayer, but creates defects at the microstructural level (microdomain boundaries) as it desorbs from the membrane upon bilayer melting 30 at the primary acyl chain transition temperature (i.e., at the transition temperature of the primary bilayer lipid). The inclusion of a surface active agent such as a lysolipid lowers the phase transition temperature of a phospholipid membrane, compared to the phase transition temperature of a membrane composed solely of the phospholipid. In a liposome composed of DPPC and 35 MPPC, the phase transition temperature is lowered depending on the amount of MPPC incorporated into the gel phase bilayer; the reduction of phase transition temperature that can be achieved is limited by the amount of MPPC that can be 9 WO 99/65466 PCT/US99/12964 stably contained in the bilayer. Membranes composed of DPPC can stably contain from 1 mol% MPPC, up to about 20 mole% MPPC, 30% mole% MPPC, 40 mol% MPPC, or even 50 mol% MPPC, depending on other conditions such as the active agent contained within the liposome. 5 In liposome bilayers containing phospholipid and a surface active agent such as a lysolipid, it is preferable that the surface active agent be contained in both layers of the bilayer. This concept is illustrated in Figure 1, which schematically represents a liposome composed of DPPC and MPPC. The molecules of MPPC are present in both the exterior and the interior layer of the 10 liposome membrane bilayer. In a liposome containing surface active agent in only one layer of the bilayer, redistribution of the surface active agent to both layers of the bilayer will occur over time at temperatures above the gel transition temperature (e.g., in the liquid crystalline phase). Phase compatibility of the two (or more) components of the present 15 invention affects the processing and stability of the lipid bilayer structure. In liposomes composed primarily of DPPC (a di-chain phospholipid), to maximize compatibility and preserve the narrow melting range of the main phospholipid, a preferred lysolipid is MPPC because it is identical to the di-chain phospholipid except that it possesses only one acyl chain (Figure 11A and 11B). The present 20 inventors discovered that inclusion of this bilayer-compatible lysolipid in low concentrations (preferably 2-20 mol%), makes liposomes composed primarily of DPPC more «leaky» at the point at which the primary lipid begins to melt (i.e., the solidus line of the main phase transition), compared to liposomes composed of DPPC alone. While not wishing to be held to a single explanation, the 25 present inventors believe that gel phase bilayers are composed of microcrystalline domains; as the temperature approaches the gel-to-liquid crystalline phase transition of the lipid bilayer, membrane permeability to the entrapped drug increases at the grain boundaries of the microstructure. At the transition temperature, desorption of the lysolipid dissolved in the gel phase 3 0 microstructure enhances the membrane permeability. An additional benefit of incorporating a compatible molecule in the liposome bilayer is that the phase transition temperature of the primary lipid is not broadened, but is lowered by about a degree or more (depending on the lysolipid concentration in the bilayer). The process of forming the mixed component liposomes of the present 35 invention involves preparation of gel phase liposomes containing a phospholipid, an appropriate surface active agent (such as lysolipid), and the active agent of interest. Other phase compatible components such as DSPE-PEG can optionally 10 WO 99/65466 PCT/US99/12964 be included, as discussed further below. The composition contains a percentage of lysolipid such that the surface active agent does not destabilize the membrane at processing temperatures where the bilayer is in the liquid phase, nor at physiological temperatures where the bilayer is in the gel phase. The bilayer 5 becomes unstable and permeable at temperatures just above normal human body temperature, and rapidly releases entrapped material from the liposome interior. Liposomes according to the present invention may be prepared by any of a variety of techniques that are known in the art. See, e.g., U.S. Patent No. 10 4,235,871; Published PCT applications WO 96/14057; New RRC, Liposomes: A practical approach, IRL Press, Oxford (1990), pages 33-104; Lasic DD, Liposomes from physics to applications, Elsevier Science Publishers, Amsterdam, 1993; Liposomes, Marcel Dekker, Inc., New York (1983). Entrapment of an active agent within liposomes of the present invention may also 15 be carried out using any conventional method in the art. In preparing liposome compositions of the present invention, stabilizers such as antioxidants and other additives may be used as long as they do not interfere with the purpose of the invention. 20 The amount of surface active agent (such as lysolipid) included in liposomes of the present invention is not sufficient to destabilize the membrane in the liquid phase that occurs during processing of the liposomes (prior to cooling to produce the gel phase product). In producing liposomes according to the present invention, it is preferable during processing of the liquid phase 25 membranes to maintain a concentration of surface active agent monomer both inside and outside the liposome, to avoid a concentration gradient that would deplete the lysolipid concentration in the membrane. This can be achieved by preparing the liposomal suspension from a premixed mixture in an aqueous medium containing sufficient amount of surface active agent in monomeric form, 30 (e.g., at the critical micelle concentration (CMC) of the surface active agent). A method of preparing a liposomal formulation according to the present invention comprises mixing the bilayer components in the appropriate proportions in a suitable organic solvent, as is known in the art. The solvent is then evaporated to form a dried lipid film. The film is rehydrated (at 35 temperatures above the phase transition temperature of the lipid mixture) using an aqueous solution containing an equilibrating amount of the surface active agent and a desired active agent. The liposomes formed after rehydration can be 11 WO 99/65466 PCT/US99/12964 extruded to form liposomes of a desired size, as is known in the art. For example, where liposomes composed of 80:20 DPPC:MPPC are produced, rehydration is carried out at a temperature above the phase transition temperature of this particular lipid mixture (above 39 0 C). The aqueous solution used to 5 rehydrate the lipid film comprises an equilibrating amount of lysolipid monomers (e.g.., a concentration equal to the Critical Micelle Concentration of MPPC). Conventional liposomes suffer from a relatively short half life in the blood circulation due to their rapid uptake by macrophages of the liver and spleen (organs of the reticuloendothelial system or RES), and therefore do not o10 accumulate in leaky tumor tissue. Liposome preparations have been devised which avoid rapid RES uptake and which have increased circulation times. STEALTH® liposomes (Sequus Inc., Menlo Park CA) include polyethyleneglycol (PEG)-grafted lipids at about 5 mol% in the lipid bilayer. See, e.g., Allen, UCLA Symposium on Molecular and Cellular Biology, 89:405 15 (1989); Allen et al., Biochim. Biophys. Acta 1066:29 (1991); Klibanov et al., FEBS Letters 268:235 (1990); Needham et al., Biochim. Biophys. Acta 1108:40 (1992); Papahadjopoulos et al., Proc. Natl. Acad. Sci. USA 88:11460 (1991); Wu et al., Cancer Research 53:3765 (1993); Klibanov and Huang, J. Liposome Research 2:321 (1992); Lasic and Martin, Stealth Liposomes, In: Pharmacology 20 and Toxicology, CRC Press, Boca Raton, Florida (1995). See also US Patent No. 5,225,212 to Martin et al.; US Patent No. 5,395,619 to Zalipsky et al. regarding liposomes containing polymer grafted lipids in the vesicle membrane. The presence of polymers on the exterior liposome surface decreases the uptake of liposomes by the organs of the RES. 25 Liposomes of the present invention may be formulated to include polymer-grafted lipids, as is known in the art, to decrease liposome uptake by the RES and thus increase the circulation time of the liposomes. Suitable polymers include hydrophilic polymers such as polyethylene glycol, polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid, and 30 polyvinyl alcohols. Active Agents As used herein, an active agent ‘in the interior’ or ‘entrapped within’ the liposome is that which contained in the interior space of the liposome, compared to 35 that partitioned into the lipid bilayer and contained within the vesicle membrane itself. As used herein, an active agent ‘within’ or ‘entrapped within’ the lipid bilayer of a liposome is carried as a part of the lipid bilayer, as opposed to being 12 WO 99/65466 PCT/US99/12964 contained in the interior space of the liposome. Active agents may be in any form suitable for use in liposomes, as is known in the art, including but not limited to aqueous solutions of active agents. Aqueous solutions of active agents within liposomes of the present invention may be at the same osmotic pressure as that of 5 the body fluid of the intended subject, or at an increased osmotic pressure (see US Patent No. 5,094,854); the aqueous solutions may also contain some precipitated active agent, as is known in the art. A preferred active agent for encapsulation in the interior of the liposome is any water soluble, weak base agent. The incorporation of certain active agents (such as some anesthetics) in 10 liposomes of the present invention may additionally alter (enhance or inhibit) the release of contents from the liposome, or alter the transition temperature of the liposome, compared to that which would be seen in a similar liposome that did not contain the active agent. The administration of antineoplastic or antitumor drugs such as 15 doxorubicin, cisplatin and methotrexate using thermosensitive liposomes in combination with hyperthermia at the desired target site has been reported. See, e.g., Magin and Weinstein In: Liposome Technology, Vol. 3, (Gregoriadis, G., ed.) p. 137, CRC Press, Boca Raton, FL (1993); Gaber et al., Intl. J. Radiation Oncology, Biol. Physics, 36(5):1177 (1996). 20 Active agents suitable for use in the present invention include therapeutic drugs and pharmacologically active agents, nutritional molecules, cosmetic agents, diagnostic agents and contrast agents for imaging. As used herein, active agent includes pharmacologically acceptable salts of active agents. Suitable therapeutic agents include, for example, antineoplastics, antitumor agents, 25 antibiotics, antifungals, anti-inflammatory agents, immunosuppressive agents, anti-infective agents, antivirals, anthelminthic, and antiparasitic compounds. Methods of preparing lipophilic drug derivatives which are suitable for liposome formulation are known in the art (see e.g., US Patent No. 5,534,499 to Ansell, describing covalent attachment of therapeutic agents to a fatty acid chain of a 30 phospholipid). In treating tumors or neoplastic growths, suitable compounds may include anthracycline antibiotics (such as doxorubicin, daunorubicin, carinomycin, N acetyladriamycin, rubidazone, 5-imidodaunomycin, N30 acetyldaunomycin, and epirubicin) and plant alkaloids (such as vincristine, vinblastine, etoposide, 35 ellipticine and camptothecin). Other suitable agents include paclitaxel (TAXOL®; a diterpenes isolated from the bark of the yew tree and representative of a new 13 WO 99/65466 PCT/US99/12964 class of therapeutic agents having a taxane ring structure) and docetaxol (taxotere); mitotane, cisplatin, and phenesterine. Anti-inflammatory therapeutic agents suitable for use in the present invention include steroids and non-steroidal anti-inflammatory compounds, such 5 as prednisone, methyl-prednisolone, paramethazone, 11-fludrocortisol, triamciniolone, betamethasone and dexamethasone, ibuprofen, piroxicam, beclomethasone; methotrexate, azaribine, etretinate, anthralin,psoralins; salicylates such as aspirin; and immunosuppresant agents such as cyclosporine. Antiinflammatory corticosteroids and the antiinflammatory and 10 immunosuppressive agent cyclosporine are both highly lipophilic and are suited for use in the present invention. Additional pharmacologic agents suitable for use in liposomes of the present invention include anesthetics (such as methoxyflurane, isoflurane, enflurane, halothane, and benzocaine); antiulceratives(such as cimetidine); 15 antiseizure medications such as barbituates; azothioprine (an immunosuppressant and antirheumatic agent); and muscle relaxants (such as dantrolene and diazepam). Imaging agents suitable for use in the present liposome preparations include ultrasound contrast agents, radiocontrast agents (such as radioisotopes or 20 compounds containing radioisotopes, including iodo-octanes, halocarbons, and renograf in), or magnetic contrast agents (such as paramagnetic compounds). Nutritional agents suitable for incorporation into liposomes of the present invention include flavoring compounds (e.g., citral, xylitol), amino acids, sugars, proteins, carbohydrates, vitamins and fat. Combinations of nutritional 25 agents are also suitable. Administration and Liposome Size Liposomes of the present invention may be administered using methods that are known to those skilled in the art, including but not limited to 30 delivery into the bloodstream of a subject or subcutaneous administration of liposomes. Where liposomes according to the present invention are used in conjunction with hyperthermia, the liposomes may be administered by any suitable means that results in delivery of the liposomes to the treatment site. For example, liposomes may be administered intravenously and thereby brought to 35 the site of a tumor by the normal blood flow; heating of this site results in the liposomal membranes being heated to the phase transition temperature so that the liposomal contents are preferentially released at the site of the tumor. 14 WO 99/65466 PCT/US99/12964 Where treatment of a tumor or neoplasm is desired, effective delivery of a liposome-encapsulated active agent via the bloodstream requires that the liposome be able to penetrate the continuous (but «leaky») endothelial layer and underlying basement membrane surrounding the vessels supplying blood to a 5 tumor. Liposomes of smaller sizes have been found to be more effective at extravasation into tumors through the endothelial cell barrier and underlying basement membrane which separates a capillary from tumor cells. See, e.g., US Patent No. 5,213,804 to Martin et al. As used herein, «solid tumors» are those growing in an anatomical site 10 other than the bloodstream (in contrast to blood-borne tumors such as leukemias) Solid tumors require the formation of small blood vessels and capillaries to nourish the growing tumor tissue. In accordance with the present invention, the anti-tumor or anti-neoplastic agent of choice is entrapped within a liposome according to the present 15 invention; the liposomes are formulated to be of a size known to penetrate the endothelial and basement membrane barriers. The resulting liposomal formulation can be administered parenterally to a subject in need of such treatment, preferably by intravenous administration. Tumors characterized by an acute increase in permeability of the vasculature in the region of tumor growth 20 are particularly suited for treatment by the present methods. Administration of liposomes is followed by heating of the treatment site to a temperature that results in release of the liposomal contents. Where site-specific treatment of inflammation is desired, effective liposome delivery of an active agent requires that the liposome have a long blood 25 halflife, and be capable of penetrating the continuous endothelial cell layer and underlying basement membrane surrounding blood vessels adjacent to the site of inflammation. Liposomes of smaller sizes have been found to be more effective at extravasation through the endothelial cell barrier and into associated inflamed regions. See, e.g., US Patent No. 5,356,633 to Woodle et al. In accordance 30 with the present invention, the anti-inflammatory agent of choice is entrapped within a liposome according to the present invention; the liposomes are formulated to be of a size known to penetrate the endothelial and basement membrane barriers. The resulting liposomal formulation can be administered parenterally to a subject in need of such treatment, preferably by intravenous 35 administration. Inflamed regions characterized by an acute increase in permeability of the vasculature in the region of inflammation, and by a localized 15 WO 99/65466 PCT/US99/12964 increase in temperature, are particularly suited for treatment by the present methods. It will further be appreciated that the liposomes of the present invention may be utilized to deliver of anti-infective agents to sites of infection, via the 5 bloodstream. The use of liposomes containing a vesicle-forming lipid derivatized with a hydrophilic polymer, and having sizes ranging between 0.07 and 0.2 microns, to deliver therapeutic agents to sites of infection is described in published PCT patent application WO 93/19738. In accordance with the present invention, the anti-infective agent of choice is entrapped within a liposome 10 having a membrane according to the present invention, and the resulting liposomal formulation is administered parenterally to a subject, preferably by intravenous administration. If desired, localized hyperthermia may be induced at the site of infection to cause the preferential release of liposomal contents at that site. 15 The size of liposomes in a preparation may depend upon the active agent contained therein and/or the intended target. Liposomes of between 0.05 to 0.3 microns in diameter, have been reported as suitable for tumor administration (US Patent No. 5,527,528 to Allen et al.) Sizing of liposomes according to the present invention may be carried out according to methods known in the art, and 20 taking into account the active agent contained therein and the effects desired (see, e.g., US Patent No. 5,225,212 to Martin et al; US Patent No. 5,527,528 to Allen et al). A preferred embodiment of the present invention is a liposome of less than 10 microns in diameter, or a liposome preparation containing a plurality liposomes of less than 10 microns in diameter. In a further preferred 25 embodiment of the present invention, liposomes are from about 0.05 microns or about 0.1 microns in diameter, to about 0.3 microns or about 0.4 microns in diameter. Liposome preparations may contain liposomes of different sizes. In another preferred embodiment of the present invention, liposomes are from about 50 rnm, 100 nm, 120 nm, 130 m, 140 nm or 150 nm, up to about 30 175 nim, 180 nm, 200 nm, 250 nmin, 300 nm, 350 nm, 400 nm or 500 nm in diameter. In one aspect of the present invention, the liposomes are prepared to have substantially homogeneous sizes in a selected size range. One effective sizing method involves extruding an aqueous suspension of the liposomes through a 35 series of polycarbonate membranes having a selected uniform pore size; the pore size of the membrane will correspond roughly with the largest sizes of liposomes 16 WO 99/65466 PCT/US99/12964 produced by extrusion through that membrane. See e.g., US Patent No. 4,737,323 (12 April 1988). In a further aspect of the present invention, liposomes are dispersed in physiological saline or PBS to provide an aqueous preparation of liposomes. The 5 aqueous preparation may further include an equilibrating amount of the surface active agent contained in the liposome bilayer, to reduce or prevent loss of the surface active agent from the liposome bilayer into solution. Liposomes composed of DPPC:MPPC may be contained in physiological saline or PBS that contains from about lmmM to about 5 mM of MPPC monomer. 10 The amount of active agent to be entrapped within or carried by liposomes according to the present invention will vary depending on the therapeutic dose and the unit dose of the active agent, as will be apparent to one skilled in the art. In general, however, the preparation of liposomes of the present invention is designed so the the largest amount of active agent possible is 15 carried by the liposome. Liposomes of the present invention may be of any type, however, LUVs are particularly preferred. Assessing Release of Liposome Contents Characterization of thermosensitive liposomes by the release of an 20 entrapped fluorescent probe, 6- Carboxyfluorescein (CF), was reported in Merlin, Eur. J. Cancer 27(8): 1031 (1979). CF was entrapped into liposomes at a quenching concentration (50 mM); no fluorescence was observed for CF entrapped in the liposome. Intense fluorescence, however, developed upon release of the probe from liposomes due to dilution of the CF in the suspension. 25 The amount of the probe released from the liposomes at various temperatures could thus be quantified based on fluorescence. Merlin, Eur. J. Cancer., 27(8):1031 (1991), studied thermally sensitive liposomes encapsulating Doxorubicin (DX), and incorporated pegylated lipids in the bilayer to increase their circulation time in the blood stream compared to conventional 3 0 thermosensitive liposomes. See also Maruyama et al., Biochem. Biophys. Acta, 1149:17 (1993)). The examples which follow are set forth to illustrate the present invention, and are not to be construed as limiting thereof. 17 WO 99/65466 PCT/US99/12964 EXAMPLE 1 Preparation of Temperature – Sensitive Liposomes DPPC liposomes containing varied molar concentrations of the lysolipid 5 Monopalmitoylphosphatidylcholine (MPPC) were prepared and characterized. The aqueous fluorescent probe 6-Carboxyfluorescein (CF) was entrapped within the liposomes to act as a marker for membrane permeability change; CF was incorporated into the liposomes using methods known in the art (See, e.g., Liposomes: A Practical Approach (1990), Editor: R.R.C. New, IRL Press, 10 Oxford, NY). The liposome components were dissolved in chloroform (a suitable organic solvent), and the solvent was evaporated under vacuum at 45 0 C using a rotavapor to form a uniform thin film of lipids on the inner walls of a round bottom flask. The lipid film was further dried under vacuum for 25 hours to ensure complete removal of traces of chloroform. 15 The lipid film was hydrated at 45’C with an aqueous solution of 10 mM PBS (pH=7.4) containing 50 mM CF and 1 mM MPPC. For efficient hydration, a TEFLON® bead was used to gently etch the lipids in the presence of aqueous medium to form a cloudy suspension of multilamellar vesicles (MLVs). The MLVs thus formed had an average size of 700 nm and were extruded through a 20 stack of two polycarbonate membrane filters of 0.1 micrometers under 300-400 psi pressure at 45 0 C (i.e., above the gel-liquid crystalline temperature of the lipid or lipid mixture) as described in the method developed by Hope et al. (Biochem. Biophys. Acta 812:55-65 (1985)) to obtain Large Unilamellar Vesicles by Extrusion Technique (LUVETs) of the desired 140nm size. The mean 25 diameter of the vesicles was measured by Photon Correlation Spectrometer (PCS, Coulter, N4 plus) after each extrusion pass. As shown in Figure 2, the size of liposomes decreased with successive passes through the membrane and reached the minimum size after three passes. 3 0 EXAMPLE 2 Release of Liposomal Contents The in vitro stability and thermosensitivity of the liposomal formulations prepared as described in Example 1 and containing various molar fractions of 35 MPPC was assessed by measuring the percent release of entrapped water soluble fluorescent molecule, CF, from the aqueous interior of the vesicle to the surrounding solution as a function of incubation temperature (25-45′ C) in the 18 WO 99/65466 PCT/US99/12964 presence of PBS. The fluorescence of CF entrapped in the liposomes was self quenched due to its high concentration, but upon release from the liposomes and dilution into the suspending medium, CF developed an intense fluorescence. After incubation, the fluorescence intensity of the samples was measured at 5 excitation wavelength (%ex) = 470 nm and emission wavelength ()em) = 520 nm after suitable dilutions to determine the amount of CF released from the liposomes. The relative percent fluorescence intensity due to incubation at a particular temperature was calculated by comparison with the total release of entrapped material obtained after disruption of the liposome samples by adding 10 10% Triton X-100. This experiment was carried out for liposomes composed of pure DPPC and for liposomes composed of DPPC:MPPC mixtures containing 2, 4, 6, 7, 8, 10 or 20 mol% MPPC, over the temperature range 20 0 C to 45 0 C. The amount of entrapped CF released from liposomes of the present 15 invention was measured as a function of time at physiological (370 C) and hyperthermic (400 C) temperatures. Liposomes were incubated in PBS for various time intervals and the release of CF was measured fluorimetrically at Xex= 470 nm and Xem=520 nm. Typical heating runs are shown in Figure 3, for the 90:10 DPPC:MPPC composition. At 370 C the percent release of CF was 20 negligible. However, on incubation at 40 0 C, about 60 % of the entrapped CF was released within five minutes; additional contents release only increased slightly upon further incubation at this temperature. Thus at a given temperature, most of the contents are released within the first five to ten minutes of heating. Figure 4 shows the release of CF from liposomes incubated for five 25 minutes at temperatures of 20 0 C to 45 0 C in the presence of 10mM PBS (pH=7.4). Release of CF was measured fluorimetrically at Xex= 470 nm and Xem=520 nm. The percent of CF released was calculated by comparing the values obtained with those obtained after the total release of CF (achieved by the addition of Triton X-100 to the liposome sample to dissolve the liposomes and 30 release all entrapped CF). Pure DPPC liposomes were stable up to 39.50 C but became permeable near the transition temperature of the phospholipid, thus causing release of some of the CF. The amount of CF released from the pure DPPC liposome was, however, only about 20% of total contents. In contrast, with increasing concentrations of MPPC in the DPPC bilayers, liposomes 35 showed an increasing release of CF, with maximum release occurring for the liposomes having bilayers containing 10 mol% and 20 mol% MPPC. 19 WO 99/65466 PCT/US99/12964 These results demonstrate that the incorporation of as little as 10 mol% of MPPC into the membranes of DPPC liposomes increases the amount of CF released by a factor of 4 (compared to the release that is seen for liposomes of DPPC alone), allowing release of up to 90% of the liposomal contents. 5 The temperature release profiles also show an additional benefit of incorporating MPPC into DPPC liposome membranes, in that the onset temperature for release is shifted to slightly lower temperatures, starting at approximately 380 C for liposomes containing 10 mol% and 20 mol% MPPC. The release profile is sharp for these liposomes, and the maximum amount of CF 10 is released after a rise in temperature of only a degree or so, i.e., at between 38.5*C and 40’C for the 10% MPPC liposomes. These experiments demonstrate that the inclusion of MPPC in liposome bilayers made of DPPC increases the amount of contents released from the interior of the liposome, and shifts the temperature range over which release 15 occurs into the range of 38.5°C – 40°C, which is the mild hyperthermic range. In DPPC liposomes containing MPPC concentrations of more than 20 mol%, the liposomes became intrinsically unstable and therefore unable to retain entrapped material at temperatures above the lipid phase transition (i.e., in the liquid phase of the lipid bilayer that occurs during processing of liposomes). 20 Such high concentrations of MPPC can also destabilize the gel phase bilayers at temperatures below the transition temperature. As demonstrated previously, the mechanical strength of membranes decreases as more and more MPPC is included (Needham et al., Biophys. J. 73:2615 (997)), and the bilayers eventually make a transition to a pure micelle suspension as the mole ratio of 25 MPPC to phospholipid goes beyond 50 mol% (Zhelev et al., Biophys. J. (in press; 1998)). One preferred molar ratio for thermally sensitive liposomes is 90:10, DPPC:MPPC. EXAMPLE 3 30 Phase Transition Behavior of DPPC/MPPC Mixtures and Correlations with Release Temperatures To investigate the biophysical mechanism involved in the permeability of the liposomes of the present invention, differential scanning calorimetric (DSC) 35 studies were carried out to generate differential calorimetric thermograms for the present liposomes, to determine the phase transition temperature. These results were compared with the release versus temperature scans obtained from cumulative release profiles (shown in Figure 4). Figures 5A and 5B show the 20 WO 99/65466 PCT/US99/12964 heat flow thermograms for liposome preparations containing increasing concentrations of MPPC in DPPC bilayers. These thermograms show that the transition temperature remains unbroadened even though up to 10% of MPPC are included in the bilayer. At a higher level of resolution, Figure 5B shows the 5 change in the peak of the transition temperature from 41.9 0 C to 41.04″C as the MPPC composition is increased from zero to 10 mol% in DPPC bilayers. Also shown is the breadth of the transition, represented as the start and end point of the transition, i.e., the solidus and liquidus lines below and above the excess heat flow peak. 10 The differential scanning thermogram of liposomes of the present invention can be compared with the differential release profiles. Figure 6A shows the cumulative release profile for CF release from the DPPC:MPPC 90:10 liposomes versus temperature, and the heat flow thermogram over the same temperature range. Figure 6B shows the differential release, which highlights the 15 sharpness of the release profile and the temperature at which maximum release occurs in relation to the heat flow thermogram. What is striking about this comparison is that that the peak release of contents obtained from the differential release profiles was 0.9 0 C lower than the peak in the transition enthalpy obtained by DSC. The release of the entrapped material at the temperature prior to Tc 20 can be attributed to the fact that the release is occurring at the ‘solidus’ line of the thermogram and not at the peak temperature. One explanation for such a behavior is that the release of entrapped material occurs as soon as the ‘first defects’ (melting defects) in the microdomain boundaries of the bilayer network appear; it is here that the lysolipid may exert its effects. While not wishing to be 25 held to a single theory, the present inventors suspect that as the transition temperature is approached the first parts of the microstructure that melt are at the grain boundaries of the solid membrane. When surrounded by a lysolipid-free aqueous phase, the lysolipid is trapped in the gel phase but can desorb when the membrane begins to melt; as it does so it enhances the defect permeability and 3 0 the contents are released more effectively than in liposomes of pure lipid alone. EXAMPLE 4 Entrapment and Release of Doxorubicin 35 Doxorubicin (DX) was entrapped into the inner aqueous volumes of liposomes of the present invention (DPPC:MPPC 90:10) using the pH gradient driven encapsulation protocol (L.D. Mayer et al (1989) Cancer Res., 42:4734.). 21 WO 99/65466 PCT/US99/12964 Briefly, a lipid composition of 90:10 DPPC:MPPC was dissolved in chloroform and the solvent was evaporated under vacuum at 45 0 C using a rotavapor. The lipid film obtained after further drying in the vacuum desiccator overnight was hydrated with 300 mM citrate buffer (pH 4.00) and the multilamellar vesicles 5 formed were subjected to seven freeze-and-thaw cycles. The resulting suspension was extruded through two polycarbonate membrane filters of pore size 0.1 pM at 50 0 C using 300-400 psi pressure. The extruded liposomes were allowed to cool to room temperature and the pH was raised to 7.5 – 8.0 using 0.5 M Na 2
CO
3 solution. 10 The extruded liposomes were incubated at 60 0 C for five minutes before adding pre-heated DX to the suspension. Samples were further heated for 10 minutes at 60’C with intermittent vortexing. The unentrapped drug was removed by mini-column centrifugation using Sephadex G-50 gel. The DX entrapped liposomes were characterized by the release of DX 15 from liposomes in the presence of PBS as a function of time at 370 and 40’C, as well as by the cumulative release profiles of entrapped DX from the liposomes at various temperatures between 250-450 C. Figure 7 represents the release of entrapped DX from liposomes as a function of time at 37*C and 40*C. the liposomes were incubated at 370 and 40’C for 30 minutes and the fluorescence 20 intensity of the released DX was measured after suitable dilutions at Xex= 470 nm and Xem= 585 nm. The percent release was calculated by comparing these values with values for the total release of 6-Carboxyfluorescein (obtained by the addition of Triton X-100 to the liposome sample). As can be seen from Figure 7, about 14% of the DX was released at 37 0 C after 30 minutes of incubation, 25 whereas 73% of the drug was released at 40 0 C after 30 minutes. As with the above studies (Examples 1-3) using CF, the cumulative release of DX entrapped in DPPC:MPPC 90:10 liposomes was measured by incubating the samples at various temperatures between 25 0 -45 0 C for five minutes and measuring the released DX fluorimetrically, as shown in Figure 8. 30 The results showed about 23 % release of DX up to 39°C and reached 65 % release at 40 0 C. EXAMPLE 5 Inclusion of PEG in Liposome Bilayers 35 Liposomes of the present invention were modified to render them less 22 WO 99/65466 PCT/US99/12964 recognizable by the RES, thereby enhancing their half life in the blood circulation. The surface of liposomes containing DPPC:MPPC 90:10 was modified by incorporating 5 mol % of DSPE-PEG (M.W. 2000) (Figure 11C) in the 5 liposome composition. Thus, the modified composition of these liposomes was DPPC:MPPC:DSPE-PEG-2000 (85.935:9.545:4.520). EXAMPLE 6 Influence of Biological Fluids 10 on Release of Liposome Contents Surface-modified liposomes as described in Example 5 were characterized by studying the release profiles of CF entrapped in the aqueous interior liposomal region in the presence of either PBS or 50% bovine serum. The 15 fluorescent intensity of released CF was measured at kex = 470 nm and kem = 520 nm, and the percent release was calculated as described in Example 3. Figures 9A shows the release of entrapped CF at 370 to 40 0 C as a function of time, in the presence of PBS. Figure 9B shows the release of entrapped CF at 370 to 40 0 C as a function of time, in the presence of 50% 20 bovine serum. The surface modified liposome formulation of the present invention was stable at physiological temperature (37 0 C) in the presence of PBS and serum, showing 1% and 7% of CF release, respectively. However, incubation of these liposomes at 40 0 C showed 64% (in PBS) and 76% (in serum) release of entrapped CF after five minutes of incubation, and reached 77% (in 25 PBS) and 92% (in serum) after 30 minutes’ incubation. Cumulative release profiles of entrapped CF from liposomes in the presence of PBS and 50% bovine serum showed 58% and 73% release, respectively (Figure 10). While not wishing to be held to a single theory, the enhanced release of CF in the presence of serum could be attributable to the interaction of certain small molecule blood 30 components in the serum with the liposome surface. The foregoing examples are illustrative of the present invention, and are not to be construed as limiting thereof. The invention is described by the following claims, with equivalents of the claims to be included therein. 23

Claims (43)

1. A liposome containing an active agent, said liposome having a lipid bilayer membrane comprising phospholipid and lysolipid, wherein phospholipids are the primary lipid source for the lipid bilayer membrane and wherein lysolipid is contained in the bilayer membrane in an amount sufficient to increase the 5 percentage of active agent released at the phase transition temperature, compared to that which would occur in the absence of said lysolipid.

2. A liposome according to claim 1, wherein phospholipid and lysolipid are contained in said bilayer membrane in a ratio of from 99:1 to 70:30 by molar weight.

3. A liposome according to claim 1, wherein said phospholipid contains saturated acyl groups.

4. A liposome according to claim 1, wherein said phospholipid is dipalmitoylphosphatidylcholine (DPPC) and said lysolipid is monopalmitoylphosphatidylcholine (MPPC).

5. A liposome according to claim 1, wherein said active agent is entrapped within the liposome interior.

6. A liposome according to claim 1, wherein said active agent is entrapped within the lipid bilayer membrane.

7. A liposome according to claim 1 having a diameter of from about 50 nanometers to about 400 nanometers.

8. A liposome according to claim 1, wherein the liposome bilayer further comprises phospholipid derivatized with a hydrophilic polymer. 24 WO 99/65466 PCT/US99/12964

9. A liposome according to claim 8, wherein said hydrophilic polymer is selected from the group consisting of polyethylene glycol, polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid, and polyvinyl alcohol.

10. A liposome according to claim 1, wherein said active agent is a pharmacologically active agent, a flavor agent, a diagnostic agent, or a nutritional agent.

11. A liposome according to claim 1, wherein said active agent is a pharmacologically active agent selected from the group consisting of antineoplastic agents, anti-inflammatory agents, anti-tumor agents, immunosuppressive agents, antibiotic agents and anti-infective agents.

12. A liposome according to claim 1, wherein said active agent is selected from the group consisting of methotrexate, doxorubicin, epirubicin, daunorubicin, vincristine, vinblastine, etoposide, ellipticine, camptothecin, paclitaxel, docetaxol, cisplatin, prednisone, methyl-prednisone, and ibuprofen.

13. A liposome according to claim 1, wherein said active agent is paclitaxel.

14. A liposome according to claim 1, wherein said active agent is camptothecin.

15. A liposome having a lipid bilayer membrane comprising a phospholipid and from 2 mole percent to 30 mole percent lysolipid, wherein phospholipids are the primary lipid source for the lipid bilayer membrane.

16. A liposome according to claim 15 wherein said phospholipid is dipalmitoylphosphatidylcholine (DPPC) and said lysolipid is monopalmitoylphosphatidylcholine (MPPC). 25 WO 99/65466 PCT/US99/12964

17. A liposome according to claim 15 wherein said lipid bilayer membrane contains from 10 mole percent to 20 mole percent lysolipid.

18. A liposome according to claim 15, wherein said active agent is a pharmacologically active agent, a flavor agent, a diagnostic agent, or a nutritional agent.

19. A liposome according to claim 15, wherein said active agent is a pharmacologically active agent selected from the group consisting of antineoplastic agents, anti-inflammatory agents, anti-tumor agents, immunosuppressive agents, antibiotic agents and anti-infective agents.

20. A liposome according to claim 15, wherein said active agent is selected from the group consisting of methotrexate, doxorubicin, epirubicin, daunorubicin, vincristine, vinblastine, etoposide, ellipticine, camptothecin, paclitaxel, docetaxol, cisplatin, prednisone, methyl-prednisone, and ibuprofen.

21. A liposome according to claim 15, wherein said active agent is paclitaxel.

22. A liposome according to claim 15, wherein said active agent is camptothecin.

23. A method for preparing an active agent for hyperthermic administration, comprising entrapping an active agent in a liposome having a lipid bilayer membrane comprising phospholipids and from 1 to 30% lysolipid, wherein phospholipids are the primary lipid source for the lipid bilayer 5 membrane.

24. A method according to claim 23 wherein said lipid bilayer membrane contains from 5 mole % to 20 mole % lysolipid. 26 WO 99/65466 PCT/US99/12964

25. A method according to claim 23, wherein said active agent is entrapped within the liposome interior.

26. A method according to claim 23, wherein said active agent is entrapped within the lipid bilayer membrane.

27. A method according to claim 23, wherein said liposome bilayer further comprises phospholipid derivatized with a hydrophilic polymer.

28. A method according to claim 27, wherein said hydrophilic polymer is selected from the group consisting of polyethylene glycol, polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid, and polyvinyl alcohol.

29. A method according to claim 23, wherein said phospholipid is dipalmitoylphosphatidylcholine (DPPC) and said lysolipid is monopalmitoylphosphatidylcholine (MPPC).

30. A method according to claim 23, wherein said active agent is a pharmacologically active agent, a flavor agent, a diagnostic agent, or a nutritional agent.

31. A method according to claim 23, wherein said active agent is a pharmacologically active agent selected from the group consisting of antineoplastic agents, anti-inflammatory agents, anti-tumor agents, immunosuppressive agents, antibiotic agents and anti-infective agents.

32. A method according to claim 23, wherein said active agent is selected from the group consisting of methotrexate, doxorubicin, epirubicin, daunorubicin, vincristine, vinblastine, etoposide, ellipticine, camptothecin, paclitaxel, docetaxol, cisplatin, prednisone, methyl-prednisone, and ibuprofen. 27 WO 99/65466 PCT/US99/12964

33. A method according to claim 23, wherein said active agent is paclitaxel.

34. A liposome according to claim 23, wherein said active agent is camptothecin.

35. A liposome preparation comprising a plurality of liposomes according to claim 1 or claim 15.

36. A liposome preparation according to claim 35, wherein said liposomes are dispersed in physiological saline.

37. A liposome preparation according to claim 36, further comprising lysolipid monomer in solution.

38. A liposome preparation according to claim 35, wherein said liposomes are from about 50 nrim in diameter to about 400 nm in diameter.

39. A liposome preparation according to claim 35, wherein said liposomes are from about 100 nm in diameter to about 200 rnm in diameter.

40. A method of making liposomes containing an active agent entrapped within the liposome interior space, comprising: a) preparing a phospholipid film containing lysolipid; b) hydrating said phospholipid film with an aqueous preparation 5 containing an active agent and an equilibrating amount of lysolipid monomer to produce liposomes; wherein lysolipid is contained in the liposome membrane in an amount sufficient to increase the percentage of active agent released at the phase transition temperature of the liposome membrane, compared to that which would occur in 10 the absence of said lysolipid. 28 WO 99/65466 PCT/US99/12964

41. The method of claim 40, wherein said hydrating step is carried out at a temperature above the gel-to-liquid crystalline phase transition temperature temperature of the lipid mixture.

42. The method of claim 40, further comprising extruding said liposomes produced by step (b) to form liposomes of a desired size.

43. A method of making liposomes according to claim 40, wherein said phospholipid film further contains an active agent. 29

AU45564/99A
1998-06-18
1999-06-09
Temperature-sensitive liposomal formulation

Expired

AU749806B2
(en)

Applications Claiming Priority (3)

Application Number
Priority Date
Filing Date
Title

US09/099,668

US6200598B1
(en)

1998-06-18
1998-06-18
Temperature-sensitive liposomal formulation

US09/099668

1998-06-18

PCT/US1999/012964

WO1999065466A1
(en)

1998-06-18
1999-06-09
Temperature-sensitive liposomal formulation

Publications (2)

Publication Number
Publication Date

AU4556499A
true

AU4556499A
(en)

2000-01-05

AU749806B2

AU749806B2
(en)

2002-07-04

Family
ID=22276065
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU45564/99A
Expired

AU749806B2
(en)

1998-06-18
1999-06-09
Temperature-sensitive liposomal formulation

Country Status (10)

Country
Link

US
(1)

US6200598B1
(en)

EP
(1)

EP1089713B1
(en)

JP
(2)

JP4691253B2
(en)

AT
(1)

ATE286718T1
(en)

AU
(1)

AU749806B2
(en)

CA
(1)

CA2335250C
(en)

DE
(1)

DE69923181T2
(en)

ES
(1)

ES2238838T3
(en)

HK
(1)

HK1035673A1
(en)

WO
(1)

WO1999065466A1
(en)

Families Citing this family (104)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US20020048596A1
(en)

*

1994-12-30
2002-04-25
Gregor Cevc
Preparation for the transport of an active substance across barriers

US6726925B1
(en)

*

1998-06-18
2004-04-27
Duke University
Temperature-sensitive liposomal formulation

SI1031347T1
(en)

1999-01-27
2002-10-31
Idea Ag
Transnasal transport/immunisation with highly adaptable carriers

ES2173678T3
(en)

1999-01-27
2002-10-16
Idea Ag

VACCINATION NOT INVASIVE THROUGH THE SKIN.

WO2000056774A1
(en)

*

1999-03-19
2000-09-28
Duke University
Methods of using bioelastomers

AU5409699A
(en)

*

1999-07-05
2001-01-22
Idea Ag
A method for the improvement of transport across adaptable semi-permeable barriers

US6676930B2
(en)

1999-11-28
2004-01-13
Scientific Development And Research, Inc.
Composition and method for treatment of otitis media

US6156294A
(en)

1999-11-28
2000-12-05
Scientific Development And Research, Inc.
Composition and method for treatment of otitis media

US20040009229A1
(en)

*

2000-01-05
2004-01-15
Unger Evan Charles
Stabilized nanoparticle formulations of camptotheca derivatives

GB0002952D0
(en)

*

2000-02-09
2000-03-29
Pharma Mar Sa
Process for producing kahalalide F compounds

DE60105977T2
(en)

*

2000-02-10
2006-02-23
Liplasome Pharma A/S

LIPIDEN-BASED SYSTEMS FOR DRUG DISPENSING

US6690976B2
(en)

2000-04-13
2004-02-10
Celsion Corporation
Thermotherapy method for treatment and prevention of breast cancer and cancer in other organs

US6768925B2
(en)

2000-04-13
2004-07-27
Celsion Corporation
Method for improved safety in externally focused microwave thermotherapy for treating breast cancer

US6725095B2
(en)

2000-04-13
2004-04-20
Celsion Corporation
Thermotherapy method for treatment and prevention of cancer in male and female patients and cosmetic ablation of tissue

US6958075B2
(en)

*

2001-09-18
2005-10-25
Celsion Corporation
Device and method for treatment of tissue adjacent a bodily conduit by thermocompression

US7837720B2
(en)

*

2000-06-20
2010-11-23
Boston Scientific Corporation
Apparatus for treatment of tissue adjacent a bodily conduit with a gene or drug-coated compression balloon

US6477426B1
(en)

2000-06-20
2002-11-05
Celsion Corporation
System and method for heating the prostate gland to treat and prevent the growth and spread of prostate tumors

JPWO2002038128A1
(en)

*

2000-11-10
2004-03-11
科学技術振興事業団

Method for producing ER dispersion

US9700866B2
(en)

*

2000-12-22
2017-07-11
Baxter International Inc.
Surfactant systems for delivery of organic compounds

CA2349506C
(en)

*

2001-06-14
2009-12-08
Duke University
A method for selective expression of therapeutic genes by hyperthermia

JP4894119B2
(en)

*

2001-09-26
2012-03-14
日油株式会社

Fatty acid-containing liposome dispersion

ES2387886T3
(en)

*

2001-11-13
2012-10-03
Celator Pharmaceuticals, Inc.

Compositions that transport lipids with better blood stability

US20030129224A1
(en)

*

2001-11-13
2003-07-10
Paul Tardi
Lipid carrier compositions and methods for improved drug retention

DE60222580T2
(en)

*

2001-11-13
2008-06-12
Celator Pharmaceuticals, Inc.

LIPID CARRIER COMPOSITIONS AND METHOD FOR IMPROVED ACTIVE INGREDIENT PREVENTION

AU2003216288B2
(en)

2002-02-13
2009-09-24
Duke University
Modulation of immune response by non-peptide binding stress response polypeptides

EP1489983A4
(en)

*

2002-02-15
2010-11-10
Boston Scient Corp
Method and apparatus treating tissue adjacent a bodily conduit with thermocompression and drugs

FR2836043B1
(en)

*

2002-02-15
2004-06-04
Inst Nat Sante Rech Med

LIPID VESICLES, PREPARATION AND USES

CN101134119A
(en)

2002-05-24
2008-03-05
血管技术国际股份公司
Compositions and methods for coating medical implants

US6807446B2
(en)

2002-09-03
2004-10-19
Celsion Corporation
Monopole phased array thermotherapy applicator for deep tumor therapy

US7672704B2
(en)

*

2002-09-11
2010-03-02
Duke University
Methods and compositions for blood pool identification, drug distribution quantification and drug release verification

US7769423B2
(en)

*

2002-09-11
2010-08-03
Duke University
MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting

US20040105881A1
(en)

*

2002-10-11
2004-06-03
Gregor Cevc
Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin

GB0304367D0
(en)

*

2003-02-26
2003-04-02
Pharma Mar Sau
Methods for treating psoriasis

US7718189B2
(en)

2002-10-29
2010-05-18
Transave, Inc.
Sustained release of antiinfectives

US7879351B2
(en)

2002-10-29
2011-02-01
Transave, Inc.
High delivery rates for lipid based drug formulations, and methods of treatment thereof

CA2504317C
(en)

2002-10-29
2012-05-22
Transave, Inc.
Sustained release of antiinfectives

US20060198882A1
(en)

*

2003-03-21
2006-09-07
Yechezkel Barenholz
Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer

GB0321066D0
(en)

*

2003-09-09
2003-10-08
Pharma Mar Sau
New antitumoral compounds

WO2005034915A2
(en)

*

2003-10-03
2005-04-21
Alza Corporation
Screening method for evaluation of bilayer-drug interaction in liposomal compositions

US8784881B2
(en)

*

2004-03-05
2014-07-22
Board Of Regents, The University Of Texas System
Liposomal curcumin for treatment of diseases

GB0408958D0
(en)

*

2004-04-22
2004-05-26
Pharma Mar Sa
Convergent synthesis for kahalalide compounds

US8147867B2
(en)

2004-05-03
2012-04-03
Hermes Biosciences, Inc.
Liposomes useful for drug delivery

WO2006030523A1
(en)

*

2004-09-17
2006-03-23
Japan Science And Technology Agency
Lipid substitution method in artificial lipid double membrane, artificial lipid double membrane obtained by that method, equipment for producing artificial lipid double membrane, and ion permeation measuring equipment

JP2008519784A
(en)

*

2004-11-12
2008-06-12
イデア アクチェンゲゼルシャフト

Extended surface aggregates in the treatment of skin conditions

WO2006086992A2
(en)

*

2005-02-18
2006-08-24
Liplasome Pharma A/S
Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands

TWI388344B
(en)

*

2005-08-23
2013-03-11
Celsion Corp
Methods of storing nanoparticle formulations

US8170643B2
(en)

*

2005-11-22
2012-05-01
Bsd Medical Corporation
System and method for irradiating a target with electromagnetic radiation to produce a heated region

US7565207B2
(en)

*

2005-11-22
2009-07-21
Bsd Medical Corporation
Apparatus for creating hyperthermia in tissue

EP3067047B1
(en)

2005-12-08
2022-04-20
Insmed Incorporated
Lipid-based compositions of antiinfectives for treating pulmonary infections

US8334257B2
(en)

2005-12-20
2012-12-18
Duke University
Methods and compositions for delivering active agents with enhanced pharmacological properties

US20130172274A1
(en)

2005-12-20
2013-07-04
Duke University
Methods and compositions for delivering active agents with enhanced pharmacological properties

US8841255B2
(en)

2005-12-20
2014-09-23
Duke University
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides

US7709227B2
(en)

*

2006-01-04
2010-05-04
Phasebio Pharmaceuticals, Inc.
Multimeric ELP fusion constructs

WO2008091655A2
(en)

*

2007-01-23
2008-07-31
The Regents Of The University Of California
Methods, compositions and device for directed and controlled heating and release of agents

US20100196455A1
(en)

2007-05-04
2010-08-05
Transave, Inc.
Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof

US9333214B2
(en)

2007-05-07
2016-05-10
Insmed Incorporated
Method for treating pulmonary disorders with liposomal amikacin formulations

US9119783B2
(en)

2007-05-07
2015-09-01
Insmed Incorporated
Method of treating pulmonary disorders with liposomal amikacin formulations

US9114081B2
(en)

2007-05-07
2015-08-25
Insmed Incorporated
Methods of treating pulmonary disorders with liposomal amikacin formulations

US8323694B2
(en)

*

2007-05-09
2012-12-04
Nanoprobes, Inc.
Gold nanoparticles for selective IR heating

MX2010004259A
(en)

*

2007-10-19
2010-08-31
Pharma Mar Sa
Improved antitumoral treatments.

WO2009059449A1
(en)

*

2007-11-05
2009-05-14
Celsion Corporation
Novel thermosensitive liposomes containing therapeutic agents

EP2252315A1
(en)

*

2008-01-30
2010-11-24
Pharma Mar, S.A.
Improved antitumoral treatments

KR20100126479A
(en)

*

2008-03-07
2010-12-01
파르마 마르 에스.에이.
Improved antitumoral treatments

JP5382567B2
(en)

*

2008-05-02
2014-01-08
公立大学法人大阪府立大学

Temperature sensitive liposome

US8173621B2
(en)

*

2008-06-11
2012-05-08
Gilead Pharmasset Llc
Nucleoside cyclicphosphates

US8636978B2
(en)

*

2008-06-23
2014-01-28
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Cyclized NGR peptide compounds, compositions, and methods of their use

EP2926825A1
(en)

*

2008-06-27
2015-10-07
Duke University
Therapeutic agents comprising elastin-like peptides

WO2010017325A2
(en)

*

2008-08-05
2010-02-11
The Methodist Hospital Research Institute
Thermally-activatable liposome compositions and methods for imaging, diagnosis and therapy

SG172359A1
(en)

2008-12-23
2011-07-28
Pharmasset Inc
Nucleoside phosphoramidates

BRPI0923815A2
(en)

2008-12-23
2015-07-14
Pharmasset Inc

Purine nucleoside synthesis

PA8855701A1
(en)

2008-12-23
2010-07-27

NUCLEOSID ANALOGS

TWI598358B
(en)

2009-05-20
2017-09-11
基利法瑪席特有限責任公司
Nucleoside phosphoramidates

SG10201407329RA
(en)

*

2009-08-14
2015-01-29
Phasebio Pharmaceuticals Inc
Modified vasoactive intestinal peptides

US20110123452A1
(en)

*

2009-11-25
2011-05-26
Nanoprobes, Inc.
Metal oligomers and polymers and their use in biology and medicine

RS54368B1
(en)

2010-03-31
2016-04-28
Gilead Pharmasset Llc
Crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1-(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate

PL3290428T3
(en)

2010-03-31
2022-02-07
Gilead Pharmasset Llc
Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate

EP3290428B1
(en)

2010-03-31
2021-10-13
Gilead Pharmasset LLC
Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate

EP2566522A4
(en)

*

2010-05-03
2015-10-28
Univ Health Network
Imageable activatable agent for radiation therapy and method and system for radiation therapy

AU2011336632B2
(en)

2010-11-30
2015-09-03
Gilead Pharmasset Llc
Compounds

JP2014503575A
(en)

*

2011-01-31
2014-02-13
ナノビオティックス

Method for monitoring release of products of interest from liposomes using superparamagnetic nanoparticles

CA2873553C
(en)

2011-06-06
2020-01-28
Phasebio Pharmaceuticals, Inc.
Use of modified vasoactive intestinal peptides in the treatment of hypertension

US9775803B2
(en)

2011-10-19
2017-10-03
Samsung Electronics Co., Ltd.
Liposome comprising elastin-like polypeptide and tumor cell targeting material and use thereof

KR102025743B1
(en)

2011-12-16
2019-09-26
나노비오?스
Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof

KR102161271B1
(en)

*

2012-02-17
2020-09-29
셀젼 코퍼레이션
Thermosensitive nanoparticle formulations and method of making the same

PL2852391T3
(en)

2012-05-21
2022-04-11
Insmed Incorporated
Systems for treating pulmonary infections

MX2015006681A
(en)

2012-11-29
2016-04-06
Insmed Inc
Stabilized vancomycin formulations.

ES2825078T3
(en)

2013-03-15
2021-05-14
Univ Loma Linda

Treatment of autoimmune diseases

AU2014283264C1
(en)

*

2013-06-18
2019-08-29
THERMOSOME GmbH
Stereospecific lipids for locoregional therapy with long-term circulating stimuli-sensitive nanocarrier systems

KR20150034517A
(en)

2013-09-26
2015-04-03
삼성전자주식회사
Liposome comprising a complex of a hydrophobic active ingredient and a polypeptide, and use thereof

KR20150047336A
(en)

2013-10-24
2015-05-04
삼성전자주식회사
Nanoparticles, method for the preparation thereof, and use thereof

KR20150062652A
(en)

2013-11-29
2015-06-08
삼성전자주식회사
Sonosensitive liposome, a pharmaceutical composition comprising the same and a method of delivering an active agent into a subject using the same

ES2818824T3
(en)

2014-05-08
2021-04-14
Phasebio Pharmaceuticals Inc

Compositions comprising a VIP-ELP fusion protein for use in the treatment of cystic fibrosis

PT3142643T
(en)

2014-05-15
2019-10-28
Insmed Inc
Methods for treating pulmonary non-tuberculous mycobacterial infections

CN104587446B
(en)

*

2014-12-19
2017-04-12
华东理工大学
Temperature-sensitive lipopeptid, lipidosome containing lipopeptid and application of temperature-sensitive lipopeptid and lipidosome

US10688156B2
(en)

2015-02-09
2020-06-23
Phasebio Pharmaceuticals, Inc.
Methods and compositions for treating muscle disease and disorders

MX2017015424A
(en)

2015-05-28
2018-03-01
Nanobiotix
Nanoparticles for use as a therapeutic vaccine.

RU2020127879A
(en)

2015-10-16
2021-11-02
Ипсен Биофарм Лтд.

STABILIZING PHARMACEUTICAL COMPOSITIONS OF CAMPTOTHETECIN

CN105796497B
(en)

*

2016-04-29
2018-09-11
江西科技师范大学
A kind of preparation method of the high temperature sensitive liposome of storage-stable coix seed oil

US20190183798A1
(en)

*

2016-06-17
2019-06-20
Johnpro Biotech Inc.
Method for treating tumor

US20190300575A1
(en)

2018-03-29
2019-10-03
Deetex, LLC
Lytic peptide biosensor and methods of making and using the same

WO2019191627A1
(en)

2018-03-30
2019-10-03
Insmed Incorporated
Methods for continuous manufacture of liposomal drug products

JP2022505714A
(en)

*

2018-10-24
2022-01-14
エイピーエイ－ アドバンスト・テクノロジーズ・リミテッド

Fused liposomes for selective imaging of tumor cells

US11788091B2
(en)

2019-08-21
2023-10-17
University Of Virginia Patent Foundation
Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth

CN112545994B
(en)

*

2020-11-19
2022-10-14
河南科技大学
Synchronous preparation method of multi-chamber and single-chamber liposome with small particle size and high stability

Family Cites Families (20)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US5077056A
(en)

1984-08-08
1991-12-31
The Liposome Company, Inc.
Encapsulation of antineoplastic agents in liposomes

US4921706A
(en)

*

1984-11-20
1990-05-01
Massachusetts Institute Of Technology
Unilamellar lipid vesicles and method for their formation

JPH0714865B2
(en)

1986-10-28
1995-02-22
武田薬品工業株式会社

Liposome preparation and method for producing the same

US5755788A
(en)

1987-02-19
1998-05-26
Rutgers, The State University
Prosthesis and implants having liposomes bound thereto and methods of preparation

US4828837A
(en)

*

1987-03-30
1989-05-09
Liposome Technology, Inc.
Non-crystalline minoxidil composition, its production and application

US4921644A
(en)

*

1988-02-29
1990-05-01
Technology Unlimited, Inc.
Mucin directed lipsome

CA1335348C
(en)

1988-03-04
1995-04-25
Yasuaki Ogawa
Liposome composition

US4906476A
(en)

*

1988-12-14
1990-03-06
Liposome Technology, Inc.
Novel liposome composition for sustained release of steroidal drugs in lungs

US5013556A
(en)

*

1989-10-20
1991-05-07
Liposome Technology, Inc.
Liposomes with enhanced circulation time

US5209720A
(en)

1989-12-22
1993-05-11
Unger Evan C
Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes

US5264618A
(en)

*

1990-04-19
1993-11-23
Vical, Inc.
Cationic lipids for intracellular delivery of biologically active molecules

DE4121388A1
(en)

*

1991-02-07
1992-08-13
Nattermann A & Cie

PHARMACEUTICAL PRODUCT FOR TREATING VIRUS DISEASES

US5277913A
(en)

1991-09-09
1994-01-11
Thompson David H
Liposomal delivery system with photoactivatable triggered release

US6764693B1
(en)

1992-12-11
2004-07-20
Amaox, Ltd.
Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants

AU6833994A
(en)

*

1993-05-17
1994-12-12
Liposome Company, Inc., The
Incorporation of taxol into liposomes and gels

WO1995008986A1
(en)

1993-09-27
1995-04-06
Smithkline Beecham Corporation
Camptothecin formulations

US5736156A
(en)

*

1995-03-22
1998-04-07
The Ohio State University
Liposomal anf micellular stabilization of camptothecin drugs

KR0173089B1
(en)

1996-01-30
1999-03-20
윤덕용
Temperature sensitive liposome coated with copolymer based on n-isopropylacrylamide/octadecylacrylate/acrylic acid and process thereof

US5783566A
(en)

*

1996-05-10
1998-07-21
California Institute Of Technology
Method for increasing or decreasing transfection efficiency

US5810888A
(en)

1997-06-26
1998-09-22
Massachusetts Institute Of Technology
Thermodynamic adaptive phased array system for activating thermosensitive liposomes in targeted drug delivery

1998

1998-06-18
US
US09/099,668
patent/US6200598B1/en
not_active
Expired – Lifetime

1999

1999-06-09
DE
DE69923181T
patent/DE69923181T2/en
not_active
Expired – Lifetime

1999-06-09
CA
CA002335250A
patent/CA2335250C/en
not_active
Expired – Lifetime

1999-06-09
ES
ES99928513T
patent/ES2238838T3/en
not_active
Expired – Lifetime

1999-06-09
AU
AU45564/99A
patent/AU749806B2/en
not_active
Expired

1999-06-09
AT
AT99928513T
patent/ATE286718T1/en
active

1999-06-09
WO
PCT/US1999/012964
patent/WO1999065466A1/en
active
IP Right Grant

1999-06-09
EP
EP99928513A
patent/EP1089713B1/en
not_active
Expired – Lifetime

1999-06-09
JP
JP2000554346A
patent/JP4691253B2/en
not_active
Expired – Lifetime

2001

2001-09-11
HK
HK01106393A
patent/HK1035673A1/en
unknown

2010

2010-03-11
JP
JP2010054624A
patent/JP2010138200A/en
not_active
Withdrawn

Also Published As

Publication number
Publication date

CA2335250A1
(en)

1999-12-23

WO1999065466A1
(en)

1999-12-23

HK1035673A1
(en)

2001-12-07

EP1089713A1
(en)

2001-04-11

AU749806B2
(en)

2002-07-04

JP4691253B2
(en)

2011-06-01

EP1089713B1
(en)

2005-01-12

JP2010138200A
(en)

2010-06-24

DE69923181T2
(en)

2006-02-16

JP2002518317A
(en)

2002-06-25

ATE286718T1
(en)

2005-01-15

ES2238838T3
(en)

2005-09-01

US6200598B1
(en)

2001-03-13

DE69923181D1
(en)

2005-02-17

CA2335250C
(en)

2009-08-18

Similar Documents

Publication
Publication Date
Title

EP1089713B1
(en)

2005-01-12

Temperature-sensitive liposomal formulation

US7901709B2
(en)

2011-03-08

Temperature-sensitive liposomal formulation

Ishida et al.

1999

Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice

Maruyama et al.

1993

Enhanced delivery of doxorubicin to tumor by long-circulating thermosensitive liposomes and local hyperthermia

US5858397A
(en)

1999-01-12

Liposomal formulations of mitoxantrone

Unezaki et al.

1994

Enhanced delivery and antitumor activity of doxorubicin using long-circulating thermosensitive liposomes containing amphipathic polyethylene glycol in combination with local hyperthermia

CA2505520C
(en)

2012-07-17

Protein-stabilized liposomal formulations of pharmaceutical agents

US5800833A
(en)

1998-09-01

Method for loading lipid vesicles

EP1272225B1
(en)

2006-08-16

Lipid-based systems for targeting diagnostic agents

CA2488385A1
(en)

2003-12-18

Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)

Ishida et al.

2000

Targeting chemotherapy to solid tumors with long‐circulating thermosensitive liposomes and local hyperthermia

CN106727329B
(en)

2020-11-03

Thermosensitive nanoparticle preparation and preparation method thereof

US9980907B2
(en)

2018-05-29

Thermolabile liposome with a controlled release temperature

US20100260683A1
(en)

2010-10-14

Thermolabile liposome with controlled release temperature

US6964778B1
(en)

2005-11-15

Temperature controlled content release from liposomes

Unezaki et al.

1993

Enhanced Tumor Targeting of Doxorubicin by Ganglioside GMl-bearing Long-circulating Liposomes

Maruyama et al.

1994

Enhanced delivery and antitumor effect of doxorubicin encapsulated in long-circulating liposomes

CA2361946A1
(en)

2003-05-13

Delayed drug release using thermosensitive liposome

Maruyama et al.

1994

Doxorubicin encapsulated in long-circulating thermosensitive liposomes

Wu et al.

2007

Lipid-based nanoparticulate drug delivery systems

Woo

2005

Thermosensitive liposomal cisplatin: formulation development, in vitro characterization and in vivo plasma elimination studies

CA2361914A1
(en)

2003-05-13

Improved cholesterol-free liposomes

Legal Events

Date
Code
Title
Description

2003-03-20
FGA
Letters patent sealed or granted (standard patent)

2019-06-27
MK14
Patent ceased section 143(a) (annual fees not paid) or expired

Download PDF in English